Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Meta Expands AI Training With Employee Activity Tracking Tools 
ROCKVILLE, Md., March 15, 2017 -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate presentation at the Oppenheimer 27th Annual Healthcare Conference. Sucampo’s presentation will occur on Tuesday, March 21, 2017 at 3:20 PM Eastern Time.
Investors interested in arranging a meeting with the Company's management during this conference should contact the conference coordinator.
The presentation will be webcast live and may be accessed from the Event Calendar page of Sucampo's website at http://www.sucampo.com/investors/events-presentations/. A replay of the webcast will also be available on the Company's website for several days after the live event. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.
About Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a pipeline of product candidates in clinical development. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan, Switzerland and the U.K. For more information, please visit www.sucampo.com.
The Sucampo logo and the tagline, The Science of Innovation, are registered trademarks of Sucampo AG. AMITIZA is a registered trademark of Sucampo AG.
Follow us on Twitter (@Sucampo_Pharma). Follow us on LinkedIn (Sucampo Pharmaceuticals).
Contact: Sucampo Pharmaceuticals, Inc. Silvia Taylor Senior Vice President, Investor Relations and Corporate Affairs 1-240-223-3718 [email protected]
